<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ariizumi T</submitter><funding>Ministry of Health, Labour and Welfare</funding><funding>Moonshot Research and Development Program</funding><funding>Japan Agency for Medical Research and Development</funding><funding>Japan Society for the Promotion of Science</funding><pagination>e1012101</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10980201</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(3)</volume><pubmed_abstract>Emerging and reemerging tick-borne virus infections caused by orthonairoviruses (family Nairoviridae), which are genetically distinct from Crimean-Congo hemorrhagic fever virus, have been recently reported in East Asia. Here, we have established a mouse infection model using type-I/II interferon receptor-knockout mice (AG129 mice) both for a better understanding of the pathogenesis of these infections and validation of antiviral agents using Yezo virus (YEZV), a novel orthonairovirus causing febrile illnesses associated with tick bites in Japan and China. YEZV-inoculated AG129 mice developed hepatitis with body weight loss and died by 6 days post infection. Blood biochemistry tests showed elevated liver enzyme levels, similar to YEZV-infected human patients. AG129 mice treated with favipiravir survived lethal YEZV infection, demonstrating the anti-YEZV effect of this drug. The present mouse model will help us better understand the pathogenicity of the emerging tick-borne orthonairoviruses and the development of specific antiviral agents for their treatment.</pubmed_abstract><journal>PLoS pathogens</journal><pubmed_title>Establishment of a lethal mouse model of emerging tick-borne orthonairovirus infections.</pubmed_title><pmcid>PMC10980201</pmcid><funding_grant_id>JP23fk0108644, JP23fk0108625, JP23jf0126002</funding_grant_id><funding_grant_id>JP23H02373, JP23K20041</funding_grant_id><funding_grant_id>JP21wm0125008</funding_grant_id><funding_grant_id>23HA2010</funding_grant_id><funding_grant_id>223fa627005h0001</funding_grant_id><funding_grant_id>JP22fk0108637</funding_grant_id><funding_grant_id>JPMJMS2025</funding_grant_id><pubmed_authors>Sawa H</pubmed_authors><pubmed_authors>Tabata K</pubmed_authors><pubmed_authors>Sasaki M</pubmed_authors><pubmed_authors>Matsuno K</pubmed_authors><pubmed_authors>Ariizumi T</pubmed_authors><pubmed_authors>Orba Y</pubmed_authors><pubmed_authors>Kobayashi H</pubmed_authors><pubmed_authors>Itakura Y</pubmed_authors><pubmed_authors>Hall WW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Establishment of a lethal mouse model of emerging tick-borne orthonairovirus infections.</name><description>Emerging and reemerging tick-borne virus infections caused by orthonairoviruses (family Nairoviridae), which are genetically distinct from Crimean-Congo hemorrhagic fever virus, have been recently reported in East Asia. Here, we have established a mouse infection model using type-I/II interferon receptor-knockout mice (AG129 mice) both for a better understanding of the pathogenesis of these infections and validation of antiviral agents using Yezo virus (YEZV), a novel orthonairovirus causing febrile illnesses associated with tick bites in Japan and China. YEZV-inoculated AG129 mice developed hepatitis with body weight loss and died by 6 days post infection. Blood biochemistry tests showed elevated liver enzyme levels, similar to YEZV-infected human patients. AG129 mice treated with favipiravir survived lethal YEZV infection, demonstrating the anti-YEZV effect of this drug. The present mouse model will help us better understand the pathogenicity of the emerging tick-borne orthonairoviruses and the development of specific antiviral agents for their treatment.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-22T21:34:47.363Z</modification><creation>2025-04-06T03:34:48.402Z</creation></dates><accession>S-EPMC10980201</accession><cross_references><pubmed>38502642</pubmed><doi>10.1371/journal.ppat.1012101</doi></cross_references></HashMap>